WEBULL
News
AAPG
29.31
+2.27%
0.65
Ascentage Pharma to Present at J.P. Morgan Healthcare Conference
Reuters · 2d ago
Ascentage Pharma Group International (6855) Receives a Buy from CICC
TipRanks · 3d ago
Cementos Pacasmayo, Rezolve AI, Emerald Holding And Other Big Stocks Moving Higher On Monday
Benzinga · 3d ago
Ascentage Pharma initiated with a Buy at Lucid Capital
TipRanks · 4d ago
Weekly Report: what happened at AAPG last week (1208-1212)?
Weekly Report · 4d ago
Analysts Have Conflicting Sentiments on These Healthcare Companies: Tandem Diabetes Care (TNDM), Kestra Medical Technologies Ltd. (KMTS) and Ascentage Pharma Group International Unsponsored ADR (AAPG)
TipRanks · 12/12 12:21
Ascentage Pharma Showcases Promising Data for Olverembatinib at ASH 2025
TipRanks · 12/09 13:59
Ascentage Pharma Reports Promising Second-Line CML Results for Olverembatinib at ASH 2025
Reuters · 12/09 13:31
Reported Earlier, Ascentage Pharma Presents Updated Olverembatinib Data At ASH 2025 Showing 76.7% CCyR And 60% MMR In Second-Line CML-CP
Benzinga · 12/09 08:04
Reported Earlier, Ascentage Pharma Highlights Olverembatinib 4-Year Follow-Up At ASH 2025, Showing EFS Advantage Versus Best Available Therapy In CML-CP
Benzinga · 12/09 07:59
ASH 2025 | Ascentage Pharma Presents Four-Year Follow-Up Data from Registrational Phase II Study of Olverembatinib, Reaffirming Differentiated Long-Term Efficacy and Safety in TKI-Resistant/Intolerant CML-CP
Barchart · 12/08 18:45
ASH 2025 | Ascentage Pharma Presents First Dataset from Phase III POLARIS-1 Study of Olverembatinib in Newly Diagnosed Ph+ ALL Shows a Best MRD-Negativity CR Rate Exceeding 60%
Barchart · 12/08 18:45
ASH 2025 | Updated Data for Ascentage Pharma‘s Olverembatinib in Second-Line CML-CP Showing Encouraging Potential for Early-Line Treatment
Barchart · 12/08 18:45
Ascentage Pharma Unveils Promising Lisaftoclax Data at ASH 2025
TipRanks · 12/08 13:27
Ascentage Pharma Reports Strong Phase II Results for Lisaftoclax in BTK-Refractory CLL/SLL
Reuters · 12/08 13:02
Piper Sandler Sticks to Its Buy Rating for Ascentage Pharma Group International Unsponsored ADR (AAPG)
TipRanks · 12/08 12:16
Weekly Report: what happened at AAPG last week (1201-1205)?
Weekly Report · 12/08 09:14
Reported Sunday, Ascentage Pharma Reports Lisaftoclax Plus AZA Shows 31.8% ORR In Venetoclax–Exposed Myeloid Malignancies
Benzinga · 12/08 07:59
Ascentage Pharma presents data from Phase Ib/II study of Lisaftoclax
TipRanks · 12/08 01:55
ASH 2025 | Ascentage Pharma Presents Encouraging Data from Phase Ib/II Study of Bcl-2 Inhibitor Lisaftoclax in Venetoclax–Exposed Patients with Myeloid Malignances
Barchart · 12/07 19:10
More
Webull provides a variety of real-time AAPG stock news. You can receive the latest news about Ascentage Pharma Group International through multiple platforms. This information may help you make smarter investment decisions.
About AAPG
Ascentage Pharma Group International is an investment holding company primarily engaged in the discovery, development, and commercialization of therapies for hematologic malignancies. The Company's main products include Olverembatinib (HQP1351), Lisaftoclax (APG-2575), Alrizomadlin (APG-115), Pelcitoclax (APG-1252), APG-5918, and APG-2449. The Company's products are primarily used to treat chronic myeloid leukemia (CML), acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), acute lymphoblastic leukemia (ALL), myelodysplastic syndrome (MDS) and multiple myeloma (MM). The Company primarily conducts its businesses in domestic market.